Contour+ is designed to streamline the contouring process, fostering standardisation and consistency while significantly reducing time, as verified by independent assessments and user feedback. This tool is crafted to align clinical contouring practices with established guidelines, marking a major leap forward in the field of radiation therapy.

Cancer remains a significant health challenge in India, with projections indicating that one in nine individuals will be diagnosed with cancer during their lifetime. In 2020, the country recorded an estimated 1.39 million cancer cases, which increased to 1.46 million by 2022. By 2025, annual cases are expected to rise by 12.8%, reaching approximately 1.57 million.

MVision AI is committed to enhancing the efficiency of cancer care, ensuring that patients receive timely and tailored treatment. The integration of advanced AI solutions like Contour+ in radiation therapy is vital for improving patient outcomes.

Its GBS solution supports Radiation Oncology professionals in AI-driven contouring and includes a robust Return on Investment (ROI) strategy. This solution features three products: Contour+, Guide, and Verify.

"MVision AI is thrilled to introduce our GBS solution to India. This will significantly reduce contouring time in oncology departments, ensuring standardized and efficient patient care. Our training and validation tools will keep clinical teams updated on best practices. Being selected as the preferred vendor marks an important milestone for MVision as we expand beyond Europe and the US," says Dharani Rangaraj, CEO of MVision AI. "The CDSCO approval in India underscores the effectiveness and potential of our technology. We are dedicated to providing the best possible care to cancer patients worldwide by making our solutions accessible to all radiation oncology professionals."